DexaVETo 2mg 100ml Antiallergy for Horses, cattle, goats, swine, dogs and cats

Description

Dexaveto 2mg

Qualitative and quantitative composition

1 ml of product contains:

Active substance :

Sodium phosphate dexamethasone 2.64 mg

(equivalent to 2 mg dexamethasone base)

Excipient (s):

Sodium methyl parahydroxybenzoate 1.14 mg / ml

Pharmaceutical form

Solution for injection, clear, colorless to light yellow

Target species

Horses, cattle, pigs, goats, dogs and cats.

Pharmacodynamic properties

Dexamethasone is a glucocorticoid. The sodium phosphate salt is freely soluble in water. It has strong anti-inflammatory and anti-allergic properties, stimulates hepatic gluconeogenesis and reduces protein synthesis, regulates cardiovascular system action and induces parturition. The main side effects are immunosuppression and suppression of adrenal cortex activity. It has a very low mineralocorticoid action.

Pharmacokinetic particularities

After an intramuscular injection, dexamethasone sodium phosphate is rapidly absorbed from the injection site and then hydrolyzed, releasing dexamethasone into the plasma. Dexamethasone is then rapidly distributed in the body. Metabolism is mainly hepatic and its metabolites are excreted as glucuronide in the urine and the bile.

Indications for use, specifying the target species

Metabolism and ketosis in bovine animals, puerperal toxemia in sows, noninfectious inflammatory processes (arthritis, periarthritis, tendovaginitis, bursitis, luxation, myositis, lymphangitis and laminitis), allergic symptoms (asthma, eczema, pruritus), stress, shock and allergic reactions, the induction of parturition in ruminants in the last stage of gestation.

Contraindications

Do not use in animals with diabetes, osteoporosis, epilepsy. in case of vaccinations: consider the immunodepresive effect. Do not use in animals with intense parasitism, viral diseases, heart, kidney and stomach disorders, corneal ulceration, a history of glaucoma. Corticosteroids are not recommended for use in animals with fungal infections.

Adverse reactions (frequency and severity)

Degradation of collagen and bone tissue after prolonged use.

Adrenal cortical insufficiency and abnormalities of the hypothalamic-pituitary-adrenal axis after prolonged use.

Slow healing of wounds, skin atrophy, atony of the muscles.

Placental retention after induction of parturition.

Systemically administered corticosteroids may cause polyuria, polydipsia and polyphagia, especially in the early stages of treatment. Use of corticosteroids may delay wound healing and immunosuppressive action may weaken infection resistance or exacerbate existing infections. Corticosteroids are not recommended for use in animals with fungal infections. Using corticosteroids can cause liver enlargement (hepatomegaly) with increased liver enzymes and may increase the risk of acute pancreatitis. Other possible side effects associated with the use of corticosteroids include changes in blood biochemical and haematological parameters. Severe side effects usually occur after prolonged use and are unlikely to occur with single high doses that are generally well tolerated. Ulceration of the gastrointestinal tract may be enhanced by corticosteroids in animals receiving non-steroidal anti-inflammatory drugs.

Special precautions for use in animals

The treatment period should be as short as possible. Long treatment should be reduced slowly and gradually.

In case of infection, a specific treatment with antibiotics or chemotherapies will be initiated. In the presence of a bacterial infection, it is usually necessary to associate an antibacterial treatment. In case of viral infections, corticosteroids can accelerate the progression of the disease

Special precautions to be taken by the person administering the veterinary medicinal product to animals

Avoid the liquid used for the injection to come into direct contact with the skin. In case of self-injection, seek medical advice immediately and show the package leaflet or the label to your doctor.

Use during gestation, lactation

Gestation:

Do not administer to pregnant animals except in case of induction of parturition in cows.

Corticosteroids are not recommended for use in pregnant females. in case of early gestational administration, fetal abnormalities were observed in animals studied in the laboratory.

Administration during advanced gestation may cause abortion or premature parturition in ruminants and may have similar effects to other species.

Interactions with other medicinal products or other forms of interaction

Do not administer concomitantly with antihistamines and barbiturates (they stimulate liver enzymes and accelerate the catabolism of dexamethasone).

The effect of dexamethasone is reduced, while the barbiturate effect decreases.

Amounts to be administered and route of administration

For intramuscular, intravenous or intraarticular administration:

Equines, cattle: 5-15 ml (I.M. or I.V.)

Fowls, calves, goats, pigs: 1-3 ml (I.M. or I.V.)

Pigs, dogs, cats: 0.25-1 ml (I.M. or I.V.)

Local therapy: 1-5 ml (intraarticular)

In small animals: periarticular injection.

Overdosage (symptoms, emergency procedures, antidotes), as appropriate

High doses may cause the side effects listed above.

Reduce the dose immediately and start symptomatic treatment.

Incompatibilities, interactions with other drugs

Because there are no compatibility studies, this product should not be mixed with other veterinary medicinal products. Vaccination of animals during treatment is not recommended.

Waiting time

Meat and organs 14 days, milk 3 days.

Period of validity

Shelf life of the veterinary medicinal product packaged for commercial use: 2 years

Shelf life after first opening the immediate packaging: 28 days.

Special precautions for storage

Store in the original package at temperatures below 25 ° C.

Protect from light.

Nature and composition of the primary packaging

100 ml glass bottles.

Special precautions for disposal of unused veterinary medicinal products or waste materials derived from the use of such products

Any unused veterinary medicinal product or waste materials derived from the use of such products should be disposed of in accordance with local requirements.